文献速递消化系统肿瘤

系统化疗用于可切除或已切除结直肠癌肝转移:个体患者数据荟萃分析

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis.
PubMed 文献 · Eur J Cancer · 2025-11-01

该系统评价与个体患者数据荟萃分析纳入4项随机III期试验共821例可切除或已切除结直肠癌肝转移患者,比较手术联合系统化疗与单纯手术。系统化疗显著改善总体ITT人群、切除人群及仅术后化疗人群的无进展生存期,并改善总体ITT和切除人群的总生存期。系统化疗与肝转移诊断时间的交互作用显著,同步转移患者获益更强。

要点

  • 系统化疗显著改善可切除或已切除CRCLM患者的PFS和OS。
  • 同步肝转移患者从系统化疗中的PFS获益更强。
  • 仅术后化疗人群的PFS获益同样显著。

核心结论

  • 系统化疗改善可切除或已切除CRCLM患者的PFS,同步转移患者获益更强。

研究设计与样本

  • 系统检索PubMed和EMBASE后,对比较手术联合系统化疗与单纯手术的随机III期试验进行个体患者数据荟萃分析。
  • 共纳入4项试验(EORTC 40983/EPOC、FFCD-ACHBTH-AURC 9002、ENG、UMIN C000000013)的821例患者,其中单纯手术411例、手术联合系统化疗410例。
  • 分析在总体ITT人群、 curative-intent手术切除人群及仅接受术后化疗人群中进行,主要终点为PFS。

主要发现

  • 系统化疗改善总体ITT人群PFS(HR 0.79;95%CI 0.67-0.93,p=0.004)。
  • 系统化疗改善切除人群PFS(HR 0.77;95%CI 0.65-0.91,p=0.003)。
  • 系统化疗改善仅术后化疗人群PFS(HR 0.76;95%CI 0.61-0.95,p=0.016)。
  • 系统化疗改善总体ITT人群OS(HR 0.82;95%CI 0.68-1.0,p=0.048)和切除人群OS(HR 0.81;95%CI 0.66-1.00,p=0.046)。
  • 多变量调整预后因素后,系统化疗对总体ITT人群PFS(p<0.001)和仅术后化疗人群PFS(p=0.003)的效应仍显著;系统化疗与肝转移诊断时间对PFS存在交互作用(总体ITT p=0.027,切除人群 p=0.024)。

临床怎么用

  • 可切除或已切除CRCLM患者可考虑系统化疗以改善PFS和OS。
  • 同步肝转移患者可能从系统化疗中获得更强PFS获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases (CRCLM) is debated. MATERIAL AND METHODS: After a systematic search in PubMed and EMBASE databases, we conducted a meta-analysis of individual patient data from randomised phase III trials comparing surgery plus systemic chemotherapy with surgery alone in patients with CRCLM. Analyses were performed in the overall intention-to-treat (ITT) population, in patients who had curative-intent surgery (resected population), and in those who received post-operative chemotherapy only. The primary endpoint was progression-free survival (PFS). RESULTS: 821 patients (411 surgery alone, 410 surgery plus systemic chemotherapy) from four trials (EORTC 40983/EPOC, FFCD-ACHBTH-AURC 9002, ENG, and UMIN C000000013) were included. Systemic chemotherapy improved PFS in the overall ITT (HR 0.79; 95 %CI: 0.67-0.93, p = 0.004), in the resected (HR 0.77; 95 %CI: 0.65-0.91, p = 0.003) and in the post-operative chemotherapy only (HR 0.76; 95 %CI: 0.61-0.95, p = 0.016) populations. Systemic chemotherapy also improved overall survival (OS) in the overall ITT (HR 0.82; 95 %CI: 0.68-1.0, p = 0.048) and in the resected (HR 0.81; 95 %CI: 0.66-1.00, p = 0.046) populations. After adjusting for prognostic factors in multivariable analyses, the effect of systemic chemotherapy remained significant for PFS in the overall ITT (p < 0.001) and in the post-operative chemotherapy only (p = 0.003) populations. An interaction between systemic chemotherapy and time to diagnosis of liver metastases for PFS was found in the overall ITT (p = 0.027) and in the resected (p = 0.024) populations. CONCLUSIONS: Systemic chemotherapy improves PFS of patients with resectable or resected CRCLM. This effect is stronger for patients with synchronous metastases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bregni G, Leurquin B, Giasafaki P, et al. Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis. Eur J Cancer. 2025. PMID: 41197289. doi:10.1016/j.ejca.2025.116092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。